We serve Chemical Name:ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate CAS:848499-08-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate
CAS.NO:848499-08-1
Synonyms:ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate
Molecular Formula:C7H7Cl2NO2
Molecular Weight:208.04200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:42.09000
Exact Mass:206.98500
LogP:2.49820
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate Use and application,ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate technical grade,usp/ep/jp grade.
Related News: Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate manufacturer ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate vendor With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. ethyl 4,5-dichloro-1H-pyrrole-2-carboxylate factory Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.